FY2025 EPS Forecast for Ekso Bionics Increased by Analyst

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Ekso Bionics in a report issued on Wednesday, December 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.87) for the year, up from their previous forecast of ($0.92). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.10) EPS.

EKSO has been the topic of a number of other research reports. Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ekso Bionics currently has a consensus rating of “Hold” and an average target price of $10.50.

Ekso Bionics Stock Down 9.3%

NASDAQ:EKSO opened at $7.84 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. The firm has a market cap of $20.54 million, a P/E ratio of -1.38 and a beta of 0.71. Ekso Bionics has a fifty-two week low of $2.73 and a fifty-two week high of $14.97. The firm has a 50-day simple moving average of $5.11 and a two-hundred day simple moving average of $4.38.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.45. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. The company had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $4.16 million.

Institutional Trading of Ekso Bionics

A number of hedge funds have recently bought and sold shares of EKSO. Consolidated Portfolio Review Corp bought a new position in Ekso Bionics in the third quarter valued at about $333,000. Citadel Advisors LLC bought a new stake in shares of Ekso Bionics during the 3rd quarter valued at about $198,000. Virtu Financial LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at about $57,000. Finally, Shay Capital LLC bought a new position in shares of Ekso Bionics in the 3rd quarter worth approximately $67,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Insider Activity at Ekso Bionics

In other Ekso Bionics news, CEO Scott G. Davis sold 23,315 shares of Ekso Bionics stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the sale, the chief executive officer owned 78,777 shares of the company’s stock, valued at approximately $378,129.60. The trade was a 22.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jerome Wong sold 11,288 shares of Ekso Bionics stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the sale, the chief financial officer directly owned 26,009 shares of the company’s stock, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 6.10% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.